Genmab — Marts 2018
-
Ikke den store salgslyst.
-
Glæden varede kort.
-
Den er under bestilling.
-
Vi skal vist have nyheder før den giver sig
-
Vi danner base under lav omsætning. Det er lige efter lærebogen, men ikke specielt ophidsende.
-
Sælgerne står i hvert fald ikke i kø længere.
-
Denne er vist ny. Lidt om Darzalex på side 5 og 6 https://seekingalpha.com/article/4156076-johnson-and-johnson-jnj-presents-barclays-global-healthcare-conference-transcript?page=3
-
God morgen.:-)
-
God morgen
-
I hope we can see some data from this Dara-CyBorD study soon; Primary Completion Date was just set to March 8, 2018. Everything that was recruiting now set to Active, not recruiting . https://clinicaltrials.gov/ct2/show/study/NCT02951819?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=03%2F13%2F2018&rank=1#locn
-
Jeg faldt over denne interessante analyse fra i går:: https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-gen/genmab-shares/news/stocks-take-a-hit-how-will-genmab-a-s-cphgen-fare/ , og forfatteren er åbenbart ikke en hr-hvem-som-helst https://en.m.wikipedia.org/wiki/Daniel_S._Loeb
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind